NK
Highly rated in
14
conditions

Dr. Nancy L. Kuntz

Ann & Robert H. Lurie Children's Hospital Of Chicago
Chicago, IL
Highly rated in
14
conditions
Specialties:Pediatrics | Neurology
Experience:48 Years
Clinical Trials:Currently Recruiting for 4 Trials
Accepts:New Patients
Highly rated in
14
conditions
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Nancy L. Kuntz's experience treating your condition:
About Dr. Nancy L. Kuntz

Nancy Kuntz is a Pediatrics specialist and a Neurologist in Chicago, Illinois. Kuntz has been practicing medicine for over 48 years and is highly rated in 14 conditions, according to our data. Her top areas of expertise are Tubular Aggregate Myopathy, Congenital Fiber-Type Disproportion, X-Linked Myotubular Myopathy, and Spinal Muscular Atrophy (SMA). She is licensed to treat patients in Minnesota. Kuntz is currently accepting new patients.

Her clinical research consists of co-authoring 73 peer reviewed articles and participating in 18 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Nancy L. Kuntz it is best to call her office and ask if your insurance is accepted.

Dr. Nancy L. Kuntz accepts the following insurance:

  •  Blue Cross Blue Shield
  •  Ambetter
Call to see if your plan is accepted.
Locations
225 E Chicago Ave, Box 51, Chicago, IL 60611
Background & Education
Graduate Institution
Boston University School Of Medicine, 1975
Specialties
Pediatrics
Neurology
Licenses
Neurology with Special Qualifications in Neurology in MN
Hospital Affiliations
Northwestern Memorial Hospital
Ann & Robert H Lurie Childrens Hospital Of Chicago
Languages Spoken
English
Gender
Female
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials
A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
Enrollment Status: Recruiting
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drugs: SRP-4045 Exon 45-Skipping TreatmentSRP-4053 Exon 53-Skipping Treatment
Study Phase: Phase 3
A Phase 3b Study to Evaluate Higher Dose Nusinersen (BIIB058) in Patients With Spinal Muscular Atrophy Previously Treated With Risdiplam
Enrollment Status: Recruiting
Publish Date: October 24, 2022
Intervention Type: Drug
Study Drug: Nusinersen
Study Phase: Phase 3
Escalating Dose and Randomized, Controlled Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy
Enrollment Status: Recruiting
Publish Date: June 30, 2022
Intervention Type: Drug
Study Drug: Nusinersen
Study Phase: Phase 2/Phase 3
TAM4MTM: A Phase 1/2 Randomized, Placebo-Controlled, Double-Blinded, Single Crossover Study to Determine the Safety and Efficacy of Tamoxifen Therapy for Myotubular Myopathy (XLMTM)
Enrollment Status: Recruiting
Publish Date: June 23, 2021
Intervention Type: Drug
Study Drug: ApoTamox
Study Phase: Phase 1/Phase 2
A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy (EMBARK)
Enrollment Status: Active, not recruiting
Publish Date: November 15, 2022
Intervention Type: Genetic
Study Phase: Phase 3
An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051
Enrollment Status: Terminated
Publish Date: August 24, 2022
Intervention Type: Drug
Study Drug: SRP-5051
Study Phase: Phase 1/Phase 2
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Enrollment Status: Completed
Publish Date: August 16, 2022
Intervention Type: Biological
Study Phase: Phase 3
Duchenne Muscular Dystrophy: Double-blind Randomized Trial to Find Optimum Steroid Regimen
Enrollment Status: Completed
Publish Date: August 12, 2022
Intervention Type: Drug
Study Phase: Phase 3
The RECENSUS Study: A Medical Chart Review of Patients With X-Linked Myotubular Myopathy (XLMTM)
Enrollment Status: Completed
Publish Date: July 29, 2022
Intervention Type: Other
A Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study With Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Completed
Publish Date: July 13, 2022
Intervention Type: Drug, Other
Study Drugs: VamorolonePrednisone
Study Phase: Phase 2
A Phase 1 Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 in Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Treatment
Enrollment Status: Completed
Publish Date: July 06, 2022
Intervention Type: Drug
Study Phase: Phase 1
Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting But Non-ambulatory Patients With Spinal Muscular Atrophy
Enrollment Status: Completed
Publish Date: January 05, 2022
Intervention Type: Biological
Study Phase: Phase 1
An Open-Label Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
Enrollment Status: Active, not recruiting
Publish Date: November 18, 2021
Intervention Type: Drug
Study Drug: Nusinersen
Study Phase: Phase 2
A 24-month Phase II Open-label, Multicenter Long-term Extension Study to Assess the Long-Term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Completed
Publish Date: May 20, 2021
Intervention Type: Drug
Study Phase: Phase 2
An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: January 25, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Completed
Publish Date: July 23, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Completed
Publish Date: January 02, 2019
Intervention Type: Drug
Study Phase: Phase 2
Phase 2 Historically Controlled Trial of Corticosteroids in Young Boys With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: December 21, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 14 Less Clinical Trials -
73 Total Publications
Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
Journal: JAMA neurology
Published: August 29, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
WD
Dr. William B. Dobyns
Neurology | Pediatrics
Highly rated in
57
conditions
Neurology
Pediatrics

M Health Fairview

5841 S Maryland Ave, 
Chicago, IL 
 7.5 mi

William Dobyns is a Neurologist and a Pediatrics expert in Chicago, Illinois. Dobyns has been practicing medicine for over 45 years and is highly rated in 57 conditions, according to our data. His top areas of expertise are Lissencephaly, Increased Head Circumference, Cortical Dysplasia, and Polymicrogyria. He is licensed to treat patients in Illinois and Washington. Dobyns is currently accepting new patients.

CC
Dr. Cynthia L. Comella
Neurology
Highly rated in
22
conditions
Neurology

University Neurologists

1725 W Harrison St, 
Chicago, IL 
 3.0 mi

Cynthia Comella is a Neurologist in Chicago, Illinois. Comella has been practicing medicine for over 43 years and is highly rated in 22 conditions, according to our data. Her top areas of expertise are Torticollis, Focal Dystonia, Drug Induced Dyskinesia, Parkinson's Disease, and Deep Brain Stimulation. She is licensed to treat patients in Illinois.

IK
Igor J. Koralnik
Dr. Igor J. Koralnik
Neurology
Highly rated in
14
conditions
Neurology

Northwestern Medicine

Northwestern Medicine Primary And Specialty Care Lavin Family Pavilion

259 E Erie St, 
Chicago, IL 
 0.2 mi

Igor Koralnik is a Neurologist in Chicago, Illinois. Koralnik has been practicing medicine for over 36 years and is highly rated in 14 conditions, according to our data. His top areas of expertise are Neurosyphilis, Progressive Multifocal Leukoencephalopathy, Encephalitis, CACH Syndrome, and Endovascular Embolization. He is licensed to treat patients in Illinois. Koralnik is currently accepting new patients.